TCR² Therapeutics Inc.

Address : 100 Binney St, Cambridge, Massachusetts 02142-1096, United States

Industries : Biotechnology

Website : tcr2.com

Company Description

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Specialities

Cancer Therapy
Immunology
Biotechnology
Health Care

T Cell Biology
Molecular Biology
Biotechnology: Pharmaceutical Preparations
Health, Wellness & Fitness

Financial

Employees Total : 54

Revenue (Yearly) : 2.4M

Total Funding : 269.5M

Latest Funding : 100M

Public Company : Yes

Trade Symbol : TCRR

Trade Exchange : Nasdaq

Market Cap : 2.4M

Miscellaneous

Founded in : 2015

Twitter : TCR2_Tx

Linkedin : tcr2-inc-

Email Providers : Outlook

Tech : Microsoft Office 365

Hosting : Google Cloud Hosting

Fonts : Typekit

Tech : Mobile Friendly

Hosted Forms : Gravity Forms

Last Updated : 2023-11-22

Employees

Maria Felina ( Senior Quality Assurance Documentation Associate )
Holly Caires ( Senior Research Associate )
Leigh Greenwald ( Senior QA Associate )
Karen Currier ( Senior Accountant )
Julio Gomez Rodriguez ( Principal Scientist )

Laura Gunn ( Vice President Medical Affairs )
Munisha Smalley ( Principal Scientist, Translational Sciences )
Jing Qiu ( Senior Scientist )
Michael Lofgren ( Director - Discovery & Innovation Immunology/Pre-Clinical R&D )